MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Public ClinicalTrials.gov record NCT03642626. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
Study identification
- NCT ID
- NCT03642626
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Interventions
- KYMRIAH Drug
- YESCARTA Drug
- Fludarabine 30mg/m2 4 doses Drug
- Cyclophosphamide 500 mg/m2; 2 doses Drug
- Fludarabine 30mg/m2 3 doses Drug
- Cyclophosphamide 500 mg/m2; 3 doses Drug
- Fludarabine 25mg/m2 3 days Drug
- Cyclophosphamide 250 mg/m2; 3 days Drug
- Tecartus Drug
- Abecma, Intravenous Suspension Drug
- Cyclophosphamide 900 mg/m2; 1 day Drug
- Breyanzi Injectable Product Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2018
- Primary completion
- Feb 8, 2024
- Completion
- May 31, 2028
- Last update posted
- Jan 22, 2026
2018 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Masonic Cancer Center at University of Minnesota | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03642626, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03642626 live on ClinicalTrials.gov.